載入中
HKSEHealthcareMedical - Pharmaceuticals
最新資料
HK$5.495
+HK$0.02 · +0.37%
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
最新資料
HK$5.495
+HK$0.02 · +0.37%
盤中時間採用HKT。市場資料可能有所延遲。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日內區間
目前HK$5.495
52週區間
目前HK$5.495
盤中時間採用HKT。市場資料可能有所延遲。
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
日內區間
目前HK$5.495
52週區間
目前HK$5.495
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 87.55億 CNY | 84.66億 CNY | 81.01億 CNY | 75.03億 CNY | 65.6億 CNY |
| 銷貨成本 | 71.1億 CNY | 64.25億 CNY | 57.79億 CNY | 54.66億 CNY | 47.86億 CNY |
| 毛利 | 16.45億 CNY | 20.42億 CNY | 23.21億 CNY | 20.37億 CNY | 17.74億 CNY |
| 研究與開發 | 4.4億 CNY | 4.13億 CNY | 4.19億 CNY | 3.46億 CNY | 3.41億 CNY |
| 銷售、一般及管理費用 | 3.41億 CNY | 6.08億 CNY | 12.98億 CNY | 8.15億 CNY | 6.89億 CNY |
| 營業費用 | 12.28億 CNY | 15.07億 CNY | 17.87億 CNY | 14.94億 CNY | 12.75億 CNY |
| 利息收入 | 748.65萬 CNY | 1112.55萬 CNY | 937.68萬 CNY | 1046.2萬 CNY | 877.63萬 CNY |
| 利息支出 | 4333.2萬 CNY | 3973.93萬 CNY | 4114.86萬 CNY | 4970.69萬 CNY | 5310.34萬 CNY |
| 折舊和攤銷 | 5.88億 CNY | 5.41億 CNY | 5.17億 CNY | 4.85億 CNY | 4.34億 CNY |
| 營業利益 | 3.64億 CNY | 5.34億 CNY | 5.35億 CNY | 4.77億 CNY | 4.26億 CNY |
| 淨利 | 2.9億 CNY | 4.7億 CNY | 4.97億 CNY | 4.11億 CNY | 3.49億 CNY |
公司資料更新於 2026年10月18日。
近期已公布業績
近期已公布業績
年度分割調整後的每股現金分配。
HK$0.2731
2025年（完整年度）+51.7% 自從 2021
2026年（部分年度）：HK$0.1725
HK$0.1801
2,021
HK$0.1758
2,022
HK$0.2189
2,023
HK$0.3014
2,024
HK$0.2731
2,025
HK$0.1725
2,026*
* 在現有股息歷史記錄中，該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年7月10日 | HK$0.1725Annual | 2026年7月13日 | 2026年7月31日 |
股息 | 2025年6月27日 | HK$0.2731Semi-Annual | 2025年6月30日 | 2025年7月18日 |
股息 | 2024年9月4日 | HK$0.0273Semi-Annual | 2024年9月5日 | 2024年9月27日 |
股息 | 2024年7月10日 | HK$0.2741Semi-Annual | 2024年7月11日 | 2024年7月30日 |
股息 | 2023年7月7日 | HK$0.2189Annual | 2023年7月10日 | 2023年7月26日 |
股息 | 2022年7月15日 | HK$0.1758Annual | 2022年7月18日 | 2022年8月5日 |
除息 2026年7月10日
HK$0.1725
Annual
2026年7月13日登記 · 支付日 2026年7月31日
除息 2025年6月27日
HK$0.2731
Semi-Annual
2025年6月30日登記 · 支付日 2025年7月18日
除息 2024年9月4日
HK$0.0273
Semi-Annual
2024年9月5日登記 · 支付日 2024年9月27日
除息 2024年7月10日
HK$0.2741
Semi-Annual
2024年7月11日登記 · 支付日 2024年7月30日
除息 2023年7月7日
HK$0.2189
Annual
2023年7月10日登記 · 支付日 2023年7月26日
除息 2022年7月15日
HK$0.1758
Annual
2022年7月18日登記 · 支付日 2022年8月5日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P Emerging Markets Small Cap ETFEWX22.33萬0.03%6.52億 USD0.65%US$69.48-1.19%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM15.21萬0.00%92.93億 USD0.39%US$37.85-1.59%
Dimensional - Emerging Core Equity Market ETFDFAE13.12萬0.00%96.26億 USD0.29%US$37.24-1.66%
Dimensional World ex U.S. Core Equity 2 ETFDFAX9.71萬0.00%122.94億 USD0.28%US$36.52-0.35%
Dimensional - Emerging Markets Value ETFDFEV4.88萬0.00%21.73億 USD0.46%US$40.65-1.57%State Street SPDR S&P Emerging Markets Small Cap ETFEWXDimensional - Emerging Markets Core Equity 2 ETFDFEMDimensional - Emerging Core Equity Market ETFDFAEDimensional World ex U.S. Core Equity 2 ETFDFAXDimensional - Emerging Markets Value ETFDFEVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
